Alumis

Envudeucitinib’s intended combination of strong TYK2 target inhibition and optimized tolerability can create a commercially relevant oral psoriasis therapy rather than another undifferentiated immunology entrant. If this holds, Alumis has a lead asset capable of supporting approval, partnering, or commercialization; if it fails, most of the current enterprise value loses its anchor.

Alumis’s precision data-analytics platform must generate repeatable target and indication selection, so the company is not a single-asset psoriasis story. If the platform works, failures or narrower labels in one indication are less damaging; if it does not, valuation should collapse toward the probability-weighted value of envu alone.

Management must convert the ACELYRIN merger assets and development spending into near-term regulatory or clinical value inflections before cash burn forces unattractive financing. If financing remains manageable through key readouts, shareholders retain upside; if not, dilution can transfer much of the scientific upside to new capital providers.

A-005 can add differentiated upside only if CNS-penetrant allosteric TYK2 inhibition translates into useful pharmacology and tolerability in neuroinflammatory or neurodegenerative disease. If A-005 works, Alumis gains a second TYK2 franchise path beyond dermatology and systemic immunology; if it fails, pipeline breadth is materially thinner.

Lonigutamab can justify its place in the portfolio only if subcutaneous IGF-1R targeting offers a meaningful thyroid eye disease differentiation versus incumbent and emerging IGF-1R options. If differentiated, the ACELYRIN merger added a valuable non-TYK2 asset; if not, it risks being a distraction that consumes capital without improving per-share value.